Alitretinoin: A Review in Severe Chronic Hand Eczema
Chronic hand eczema is a common but frequently disabling skin condition which poses a significant social and economic burden. Although skin protection measures and topical therapies are fundamental in its management, some patients are refractory to first-line therapy with topical corticosteroids and require systemic treatment. Alitretinoin (9-cis-retinoic acid; Toctino®) is an endogenous vitamin A derivative with high binding affinity for both retinoic acid receptors and retinoid X receptors. Alitretinoin is the first systemic treatment to be approved in the EU for use in patients with severe chronic hand eczema unresponsive to potent topical corticosteroids. This article updates an earlier review of alitretinoin in this indication, focusing on recently published data. In clinical trials, treatment with alitretinoin 10 or 30 mg once daily for up to 24 weeks improved the severity and extent of severe chronic hand eczema in adults, with significantly more alitretinoin than placebo recipients achieving ratings of ‘clear’ or ‘almost clear’ hands on the Physician Global Impression of Change scale. For the most part, data obtained in real-world studies were consistent with those observed in clinical trials. Alitretinoin was generally well tolerated, with most adverse events being reversible, dose-dependent and of mild or moderate severity. Thus, oral alitretinoin is a useful treatment option for patients with severe chronic hand eczema unresponsive to potent topical corticosteroids.
KeywordsRetinoid Topical Corticosteroid Dermatology Life Quality Index Physician Global Assessment Hand Eczema
During the peer review process, the manufacturer of alitretinoin (GlaxoSmithKline) was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflict of interest
Hannah Blair and Lesley Scott are salaried employees of Adis/Springer, are responsible for the article content and declare no relevant conflicts of interest.
- 4.Feldman SR, Phelps KC, Verzino KC. Anticancer and immunosuppressant drugs. Handbook of dermatologic drug therapy. UK: Taylor & Francis; 2005. p. 61.Google Scholar
- 7.Stiefel. Summary of product characteristics: Toctino® soft capsules. 2013. http://www.mhra.gov.uk. Accessed 13 July 2016.
- 12.Scheuermann J, Kraus LF, Frenzel DF, et al. 9-cis-retinoic acid modulates dendritic cell differentiation to generate a Treg inducing phenotype. [abstract no. P116]. Exp Dermatol. 2015;24(3):E21.Google Scholar
- 19.Ruzicka T, Lynde CW, Jemec GB, et al. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. Br J Dermatol. 2008;158(4):808–17.CrossRefPubMedGoogle Scholar
- 20.Fowler JF, Graff O, Hamedani AG. A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of alitretinoin (BAL4079) in the treatment of severe chronic hand eczema refractory to potent topical corticosteroid therapy. J Drugs Dermatol. 2014;13(10):1198–204.PubMedGoogle Scholar
- 25.Augustin M, Thaci D, Noone M, et al. Early use of alitretinoin in accordance with standard guidelines in patients with severe, refractory CHE–effect on the quality of life [abstract no. 2999892]. In: 23rd World Congress of Dermatology. 2015.Google Scholar
- 26.Thaci D, Augustin M, Noone M, et al. A focus on patients with severe CHE: influential factors on the quality of life, work productivity and progression of treatment while taking alitretinoin [abstract no. 2999752]. In: 23rd World Congress of Dermatology. 2015.Google Scholar
- 28.National Institute for Health and Care Excellence. Alitretinoin for the treatment of severe chronic hand eczema. 2009. http://www.nice.org.uk/guidance/ta177. Accessed 13 July 2016.